New pain block could keep lung surgery patients comfortable for days

NCT ID NCT07134660

Recruiting now Symptom relief Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a long-acting painkiller (liposomal bupivacaine) to a standard one (bupivacaine hydrochloride) for numbing nerves between the ribs during lung surgery. About 210 adults having keyhole lung surgery will be randomly assigned to one of three groups: the long-acting block, the standard block, or no block. The goal is to see if the long-acting version provides better pain control from 25 to 72 hours after surgery, which could reduce opioid use and help patients recover faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal bupivacaine
What this could lead to: If it works, this could provide longer-lasting pain relief after lung surgery, reducing the need for opioids and speeding recovery.
What could go wrong: This is a mid-sized trial (210 people) and the effect may be modest. The long-acting version is more expensive, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER POSTOPERATIVE PAIN, ACUTE

Contacts and locations

Locations

Shanghai pulmonary hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.